NCT06023199View on ClinicalTrials.gov

Assessing Physical Function in Sickle Cell Patients Taking Voxelotor

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

October 23, 2025

Study Completion Date

December 23, 2025

Conditions

Sickle Cell Disease

Interventions

DRUG

Voxelotor

Voxelotor is administered orally at a dose of 1500mg daily.

Trial Locations (1)

22042

Inova Schar Cancer Institute, Falls Church

Sponsors

Lead Sponsor

Inova Health Care Services

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Inova Health Care Services

OTHER